Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$71.55

+$0.13 · +0.18%

Aug 21, 4:00 PM ET

Pre-market

$70.05

−$1.50 · -2.10%

Aug 24, 8:05 AM ET

UTMD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

81

Deep Value

Momentum

51

Neutral

Sentiment

53

Mixed

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Kevin L. Cornwell
Listed since
Mar 8, 1999
Employees
146

Market position

Day range

Current $71.55

52-week range

Current $71.55

Open
$70.55
Previous close
$71.42
Volume
114.14K
5.58× average
Average volume
20.45K
Average daily volume
Market cap
227.82M USD
Beta
0.36
Market reference 1
50-day average
$69.803
+2.50% above average
200-day average
$64.0965
+11.63% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
95.78M USD
P/E (TTM)
21.81×
P/B (TTM)
1.87×
P/S (TTM)
6.31×
EV / EBITDA
5.61×
Earnings yield
6.22%
Free cash flow yield
7.90%
Dividend yield
1.73%

Profitability & efficiency

Gross margin
54.88%
Operating margin
28.46%
Net margin
29.04%
Return on equity
9.46%
Return on assets
9.21%
Return on invested capital
7.60%

Financial health

Debt / equity
Current ratio
37.62×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends66%53%39%26%Gross margin, FY2021: 63.03%Gross margin, FY2022: 61.58%Gross margin, FY2023: 59.81%Gross margin, FY2024: 59.03%Gross margin, FY2025: 51.60%Operating margin, FY2021: 38.49%Operating margin, FY2022: 37.85%Operating margin, FY2023: 33.40%Operating margin, FY2024: 33.23%Operating margin, FY2025: 29.60%Net margin, FY2021: 30.15%Net margin, FY2022: 31.51%Net margin, FY2023: 33.12%Net margin, FY2024: 33.92%Net margin, FY2025: 29.30%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 63.03%. Gross margin FY2022 61.58%. Gross margin FY2023 59.81%. Gross margin FY2024 59.03%. Gross margin FY2025 51.60%. Operating margin FY2021 38.49%. Operating margin FY2022 37.85%. Operating margin FY2023 33.40%. Operating margin FY2024 33.23%. Operating margin FY2025 29.60%. Net margin FY2021 30.15%. Net margin FY2022 31.51%. Net margin FY2023 33.12%. Net margin FY2024 33.92%. Net margin FY2025 29.30%.

Income trends

Revenue

38.52M USD-5.83%

Operating income

11.4M USD-16.12%

Net income

11.29M USD-18.65%
Income trends across reported periods56.38M USD39.98M USD23.58M USD7.19M USDRevenue, FY2021: 49.05M USDRevenue, FY2022: 52.28M USDRevenue, FY2023: 50.22M USDRevenue, FY2024: 40.9M USDRevenue, FY2025: 38.52M USDOperating income, FY2021: 18.88M USDOperating income, FY2022: 19.79M USDOperating income, FY2023: 16.78M USDOperating income, FY2024: 13.59M USDOperating income, FY2025: 11.4M USDNet income, FY2021: 14.79M USDNet income, FY2022: 16.47M USDNet income, FY2023: 16.64M USDNet income, FY2024: 13.87M USDNet income, FY2025: 11.29M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 49.05M USD. Revenue FY2022 52.28M USD. Revenue FY2023 50.22M USD. Revenue FY2024 40.9M USD. Revenue FY2025 38.52M USD. Operating income FY2021 18.88M USD. Operating income FY2022 19.79M USD. Operating income FY2023 16.78M USD. Operating income FY2024 13.59M USD. Operating income FY2025 11.4M USD. Net income FY2021 14.79M USD. Net income FY2022 16.47M USD. Net income FY2023 16.64M USD. Net income FY2024 13.87M USD. Net income FY2025 11.29M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue38.52M USD40.9M USD50.22M USD52.28M USD49.05M USD
Cost of goods sold18.65M USD16.76M USD20.19M USD20.09M USD18.14M USD
Gross profit19.88M USD24.14M USD30.04M USD32.2M USD30.92M USD
Research and development668K USD813K USD560K USD493K USD526K USD
Selling, general, and administrative7.81M USD5.57M USD12.7M USD11.91M USD11.51M USD
Operating expenses8.47M USD10.55M USD13.26M USD12.41M USD12.04M USD
Interest income3.37M USD661K USD166K USD
Depreciation and amortization2.95M USD2.77M USD6.37M USD7.08M USD7.28M USD
Operating income11.4M USD13.59M USD16.78M USD19.79M USD18.88M USD
Net income11.29M USD13.87M USD16.64M USD16.47M USD14.79M USD

Company facts updated Aug 24, 2026.

UTMD peers

ETFs holding UTMD

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research UTMD

research.disclaimer